About Us

WHO WE ARE
Genesis Research is a global Life Sciences research and consulting company dedicated to providing End-to-End Evidence Development, Management, and Communication services.

WHAT WE DO
Healthcare evidence can be categorized as foundational, demonstrative or oppositional in nature, and we take that holistic view to our clients. Through this unique perspective, we bring customized engagement approaches to support our clients. Our passion is working with our clients collaboratively, providing support for both the planned and unplanned initiatives that define the world of evidence in the 21st century.

ZERO

Projects we outsource

5

New team members in 2018

20

Areas of therapeutic
expertise

WHAT WE OFFER


OUR CLIENTS

Through our unique engagement approach we support our Life Sciences clients with research and consulting services.

Pharmaceutical and Biotechnology
Genesis provides research support to deliver evidence to satisfy regulatory requirements, payer requests, safety analyses and economic arguments throughout the product life-cycle.
As a leader in evidence development and communication, we also support our clients with unique services such as rapid response analytics, outcomes simulation, and payer data collaboration.

Medical Devices and Diagnostics
Genesis provides a range of evidence support to the Medical device, Diagnostic, and Nutritional Product market. From EMR data analytics to hospital models and outcomes analyzers, the opportunity to communicate the value of interventions is customized for the medical device and diagnostics industry.
Real World Evidence policy for medical device and diagnostic products allows for novel evidence development and communication activities. To this end, Genesis has expertise in industry best support focused on emerging safety signals, comparative effectiveness and a differentiated value story.

CLIENT TESTIMONIALS:

" It is always a pleasure to work with Genesis - they are a true partner "

" Genesis is a provider of innovative solutions "

" Genesis is an organization where I have direct contact with the experts at my convenience "

" Genesis provides the best data visualization in the industry "

Case Studies

OUTCOMES SIMULATION

Simulation of Patient-Treatment effect for various experimental cohorts

Evidence Mapping and Value Platforms

Centralized evidence resource for multiple markets

Data Analytics Support

Support for an advanced data analytic capability

Data Analytics Partnership Plus Data Analytics Platform Technology

Rapid Response RWE

Rapid Literature Review and Data Visualization

Crystallizing data for multiple stakeholders

European Database Analysis

With the goal of high profile publication

Economic model
with Graphic User Interface

An economic model that tells a compelling story

Hospital Database Analysis

Leverage rich clinical data from leading providers

GVD Rescue

Taking data and making it easy to understand

Meta Analysis and Data Visualization

Complex evidence optimized for market access strategy and lanuch success

Emerging Safety Signals

Real time safety analysis and regulatory engagement

Automated Chart Development for Treatment Pattern Analysis

Leveraging content and healthcare IT expertise

News

Sort by

Management Team

Genesis' core team of industry leaders share passion and commitment to building lasting relationships with our clients

STEVE ARIKIAN, MD

Steve has over 25 years of experience in Epidemiology and Outcomes Research, including academic appointments at Columbia University, the University of Kentucky and the University of Toronto, as well as tenure in Big Pharma and Consulting. His interests include design and implementation of large-scale database analyses, economic modeling and MetaResearch. He has designed and implemented research projects in the United States, Canada, Latin America, Europe and Australasia.
A co-founder of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Steve is widely published in the peer-reviewed literature, is a referee for numerous professional journals, and has been a frequent speaker at industry and trade group sponsored meetings on topics including Database Analytics, Pharmacoepidemiology, MetaResearch, Formulary Management, Pharmaceutical Pricing, and evaluating Product Value.

STEVE ARIKIAN, MD
Chairman & Chief Executive Officer

FRANK A. CORVINO, PHD

Specializing in epidemiology and biostatistics, Dr. Corvino consistently leverages his knowledge of real world data sources to best fit the clinical and economic outcomes of each particular analysis. His real world data expertise includes chart reviews, registry data, clinical datasets, claims and electronic health records.

FRANK A. CORVINO, PHD
Chief Operating Officer

MARKO ZIVKOVIC, PHD

Dr. Zivkovic manages a team of analysts and plays a pivotal role in the development of technology systems that support and leverage data analytics. Dr. Zivkovic has a particular interest in the development of predictive models and machine learning to facilitate the patient prioritization and clinical insights critical to healthcare management.

MARKO ZIVKOVIC, PHD
Managing Director

Julie Locklear, PharmD, MBA

Dr. Locklear Directs and manages a team of scientists, biostatisticians, and programmers to implement strategic client initiatives. in Health Economics & Outcomes Research, including data analytics, health economic modeling, simulation, and scientific communications; Market Access solutions and deliverables; Business Development evaluations; Regulatory support and C-suite strategic and innovative solutions.
Dr. Locklear was Vice President and Head of Health Economics and Outcomes Research at EMD Serono, the biopharmaceutical division of Merck KGaA Darmstadt, Germany, where she was responsible for establishing and building the US Health Economics & Outcomes Research team within the Medical Affairs organization. She also previously served as Global Payer Evidence Director at AstraZeneca, and as an Associate Director of US Health Economics and Outcomes Research at Janssen Pharmaceutica.

JULIE LOCKLEAR, PharmD, MBA
Managing Director

Michael J. Di Costanzo Jr.

Michael has served as Chief Financial Officer of Genesis Research since 2010, where he directs all financial operations including corporate accounting, financial planning and analysis, internal audit, tax, treasury, corporate development, insurance, and real estate. Born and raised in New York, Mike received his CPA degree from Fordham University and is an expert in Corporate, Partnership and Individual Taxation. His broad range of experience stretches from multi-million dollar companies to entrepreneurial startups.

MICHAEL J. DI COSTANZO JR.
Chief Financial Officer

MICHAEL LIVINGSTONE

Michael has been with the Genesis team since 2011, with increasing levels of responsibility, fostering company growth on a number of ongoing client relationships. As the Director of Operations, Michael works on talent acquisition, introduction of executable strategies and tactics to harmonize business practices with commercial goals and consolidation of cross-functional teams to deliver client solutions.

MICHAEL LIVINGSTONE
Director of Operations

Recent Publications

  • Hamzavi I, Sundaram M, Nicholson C, Zivkovic M, Parks-Miller A, Lee J, Yi J, Gu Y, Okun MM, Ganguli A, Arikian SR. “Uncovering Burden Disparity: A Comparative Analysis of Moderate to Severe Psoriasis and Hidradenitis Suppurativa Impact”. Journal of the American College of Dermatology (2017);77(6):1038-1046.
  • Mannix S; Hassan M, Tummala R, Locklear JC, Revicki DA, Khan S, Dunbar GC, Eriksson H, Sheehan, DV. "Content validity of the Sheehan Irritability Scale in patients with major depressive disorder" International Clinical Psychopharmacology. In press.
  • Laura Chu, Frank A. Corvino, Jingbo Yi, Marko Zivkovic, William Wong, "Biomarker Testing Trends and Treatment Patterns in Non-Small Cell Lung Cancer (NSCLC) Patients in the United States", Poster presented at IASLC 18thWorld Conference on Lung Cancer, Yokohama, Japan, October 15-18, 2017
  • B Cai, R Echols, F Corvino, G Morgan, D van Veenhuyzen, M Ariyasu, T Sawada, T Nagata, "Burden of Carbapenem-resistant Gram-negative Infections in US Hospitals ", Poster presented at IDWeek 2017, San Diego CA, October 4-8, 2017
  • Kelly Reveles, Jennifer Backo, Frank Corvino, Marko Zivkovic, Kelly Broderick, "Fidaxomicin versus Vancomycin as a First-Line Treatment for Clostridium difficile-Associated Diarrhea (CDAD) in Specific Patient Populations: A Pharmacoeconomic Evaluation", Accepted for publication, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
  • Pavel Napalkov, Nengjun Zhao, Frank Corvino, "Characterizing the Prevalence of Giant Cell Arteritis in the United Kingdom Using the Clinical Practice Research Datalink", Poster presented at 33rd Annual Conference ICPE 2017, Montreal QC, August 26-30, 2017
  • C Siffel, WA Blumentals, WM Spalding, M McEnany, FA Corvino, "Cohort Study Evaluating Suicidal Behavior Associated with ADHD Stimulant Therapies", Poster presented at 33rd Annual Conference ICPE 2017, Montreal QC, August 26-30, 2017
  • Melissa Yong, Matthew McEnany, Jenny Chia, Christina Lorenz, Pavel Napalkov, "Recent Age-Specific Prevalence and Incidence Time Trends of Autism Spectrum Disorder (ASD) in the United Kingdom (UK) Using the Clinical Practice Research Datalink (CPRD)", Poster presented at 33rd Annual Conference ICPE 2017, Montreal QC, August 26-30, 2017
  • Vidya Moorthy, Frank A. Corvino, Matt McEnany, Monie Hussain, Pavel Napalkov, "Time Trends in Diabetic Macular Edema Among Diabetic Adults in the United Kingdom", Poster presented at 33rd Annual Conference ICPE 2017, Montreal QC, August 26-30, 2017
  • Ching-Yi Chuo, Kyle A. Richards, Marko Zivkovic, Jingbo Yi, Thirupathi Pattipaka, Christina L. Derleth, Shih-Wen lin, "Validation of an Algorithm in Administrative Claims to Identify Adequate Intravesical Bacillus Calmette-Guerin Therapy in Elderly Patients with Non-Muscle Invasive Bladder Cancer", Poster presented at 33rd Annual Conference ICPE 2017, Montreal QC, August 26-30, 2017
  • Wong W, Burudpakdee C, Seetasith A, Corvino F, Yeh D, Gubens M, "The Economic Impact of Delaying Brain Metastases in Alk-Positive Non-Small Cell Lung Cancer in the Commercially Insured US Population", Poster presented at 22nd Annual Conference ISPOR 2017, Boston MA, May 20-24, 2017
  • E. Gluck, H. Nguyen, K. Yalamanchili, M. McCusker, J. Sherman, J. Madala, F. Corvino, R. Balk, "Epidemiology of Sepsis Biomarker Use in the United States, 2012-2015", Am J Respir Crit Care Med 2017; 195:AS013
  • Dahl NV, Kaper RF, Strauss WE, Corvino FA, Zivkovic M, “Cost-effectiveness Analysis of Intravenous Ferumoxytol for the Treatment of Iron Deficiency Anemia in Adult Patients with Non-Dialysis-Dependent Chronic Kidney Disease in the USA”, ClinicoEconomics and Outcomes Research, Vol. 2017:9 P. 557—567, September 20, 2017
  • Hamzavi I, Sundaram M, Nicholson C, Zivkovic M, Parks-Miller A, Lee J, Yi J, Gu Y, Okun MM, Arikian SR. “Uncovering Burden Disparity - A Comparative Analysis of Moderate to Severe Psoriasis and Hidradenitis Suppurativa Impact”, Journal of the American Academy of Dermatology (JAAD), 2017
  • Corvino FA, Bains S, Pulgar S, Suarez G, "Characteristics and Treatment Patterns of Pediatric Cerebral Palsy (CP) Patients in the United States", Poster presented at 2017 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), Phoenix AZ, September 13-16, 2017
  • McCusker M, Cheng M, Lee Y, Cheng I, Corvino F, Zhao N, Scudder S, "Radiographic imaging test utilization among metastatic lung cancer patients during first EGFR TKI treatment", Poster presented at 22nd Annual Conference NCCN 2017, Orlando FL, March 23-25, 2017
  • Corvino F, Oliveri D, Phillips A. The association of timing of disease-modifying drug initiation and relapse in patients with multiple sclerosis using electronic health records. Curr Med Res Opin (2017); Apr 11:1-6
  • DeZern AE, Binder G, Rizvi S, Corvino FA, Arikian SR, Surinach A, Lee J, Smith BD. “Patterns of treatment and costs associated with transfusion burden in patients with myelodysplastic syndromes”, Leukemia and Lymphoma, Vol. 58, Iss. 11, 2017
  • Richards KA, Lin SW, Chuo C, Derleth C, Zivkovic M, Ogale S, Prasad S, Decastro GJ, Steinberg G, “A Real-World Study of Patterns of Intravesical Bacillus Calmette-Guerin (BCG) Use and Outcomes in Elderly United States (US) Patients (pts) With Non-Muscle Invasive Bladder Cancer (NMIBC)", Poster presented at 112th American Urological Association (AUA) Annual meeting, Boston MA, May 12-16, 2017
  • Natalia Sadetsky, Frank Corvino, Andy Surinach, Grant Goodman, "Treatment Patterns for Patients (pts) With Melanoma Receiving Vemurafenib (VEM) in the Real-world Setting", Poster presented at 13th International Congressof the Society for Melanoma Research (SMR), Boston MA, November 6-9, 2016
  • Natalia Sadetsky, Preeti Bajaj, Andy Surinach, Dawn Colburn, "Survival Outcomes in Patients (pts) With Advanced Melanoma With CNS Metastases", Poster presented at 13th International Congressof the Society for Melanoma Research (SMR), Boston MA, November 6-9, 2016
  • Khan SA, Revicki DA, Hassan M, Locklear JC, Friedman LA, Mannix S, Tummala R, Dunbar GC, Eriksson H, Sheehan, D. Assessing the reliability and validity of the Sheehan Irritability Scale in patients with major depressive disorder. J Clin Psych (epub ahead of print); http://www.psychiatrist.com/JCP/TOC/Pages/aheadofprint.aspx.
  • R. C. Ong, R. Houghton, A. Surinach, F. Bolognani, "Pattern of Use of Psychotropic Medications in Patients with Autism Spectrum Disorder in the United States", Poster presented at 2016 International Meeting for Autism Research, Baltimore MD, May 11-14, 2016
  • R. C. Ong, R. Houghton, A. Surinach, F. Bolognani, "Mental Comorbidities and Use of Psychotropic Medications in Patients with Autism Spectrum Disorder in the United States", Poster presented at 2016 International Meeting for Autism Research, Baltimore MD, May 11-14, 2016
  • Burudpakdee, C., Lin, M., Wang, W., Seetasith, A., Zhu, Y., Bonthapally, V., & Carson, K., Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data. J Med Econ. 2016 May 26:1-8
  • Sadetsky N, Corvino F, Surinach A, Goodman G, "Clinical and demographic characteristics of patients (pts) treated with vemurafenib in real-world setting", Poster presented at 16th World Congress on Cancers of the Skin, 12th Congress of the European Association of Dermato-Oncology, Vienna Austria, August 31-September 3, 2016
  • DeZern AE, Binder G, Hu XH, Rizvi S, Corvino FA, Arikian SR, Surinach A, Lee J, Smith BD. “The Effect of Lenalidomide Dose Modification on Outcomes in Patients with Myelodysplastic Syndromes”. Abstract accepted for 21st Annual Conference NCCN 2016, Hollywood, FL, March 31-April 2, 2016
  • Gong J, George D, Mhatre S, Lin SW, Surinach A, Wallen H, Vohra R, Simpson J, Ogale S, Pal SK, “Influence of diabetes and congestive heart failure (CHF) on selection of first-line (1L) treatment for metastatic renal cell carcinoma (mRCC)”, Annals of Oncology, Volume 27, Issue suppl_6, 1 October 2016, 810P
  • Hamzavi I, Sundaram M, Arikian SR, Gu Y, Okun MM. “Uncovering Burden Disparity: A Comparative Analysis of Moderate to Severe Psoriasis and Hidradenitis Suppurativa Impact on Quality-of-Life”, Abstract accepted for 74th Annual Meeting of American Academy of Dermatology, Washington DC, March 4-8, 2016
  • Mhatre S, Lin S, Surinach A,  Vohra R, Samtram-Hoang S, Simpson J, Wallen H, Ogale S, Gong J, Pal SK, George DJ, “Health Resource Utilization (HRU) and costs for metastatic renal cell carcinoma (mRCC) patients treated with first-line (1L) systemic therapy in the United States”, Poster presented at ISPOR 19th Annual European Congress, Vienna Austria, October 29 - November 2, 2016
  • Ong RC, Houghton R, Surinach A,  Bolognani F. “Mental Comorbidities and Use of Psychotropic Medications in Patients with Autism Spectrum Disorder in the United States”, submitted to IMFAR 2016, Baltimore, MD, May 11-14, 2016
  • Ong RC, Houghton R, Surinach A,  Bolognani F. “Pattern of Use of Psychotropic Medication in Patients with Autism Spectrum Disorder in the United States”, submitted to IMFAR 2016, Baltimore, MD, May 11-14, 2016
  • Pal SK, Galsky MD, Lin SW, Ogale S, Zivkovic M, Simpson J, Derleth C, Sonpavde G, “Second-line metastatic urothelial carcinoma treatment and survival in real-world patients in the US”, Ann Oncol (2016) 27 (suppl_6): 801P
  • Phillips AL, Fang J, Corvino FA, Oliveri D. “Association of Timing of Disease-Modifying Drug Treatment Initiation on Multiple Sclerosis Relapse Rates in Newly Diagnosed Patients”, Abstract submitted to 68th Annual Meeting of the American Academy of Neurology (AAN), Vancouver, British Columbia, Canada, April 15-21, 2016
  • Sima CS, Zivkovic M, Sadetsky N, Hou J, Bergstorm D, Dawson K, Caro I, “Use of Vismodegib in the real world: Analysis of a US insurance claims database” 16th World Congress on Cancers of the Skin and 12 th Congress of the European Association of Dermato-Oncology, 2016
  • Smith BD, DeZern AE, Binder G, Rizvi S, Corvino FA, Arikian SR, Surinach A, Lee J. “Patterns of total cost for patients (pts) with active treatment (Tx) of myelodysplastic syndromes (MDS)”, Journal of Clinical Oncology 2016 34:15_suppl, e18252-e18252
  • Smith BD, DeZern AE, Binder G, Rizvi S, Corvino FA, Arikian SR, Surinach A, Lee J. “Patterns of total cost for patients (pts) with active treatment (Tx) of myelodysplastic syndromes (MDS)”, Poster presented at 21st EHA Congress, Copenhagen, Denmark, June 9-12, 2016
  • Yong M, Chia J, Oliveri D, Chen H, Cheung D, Cohen M, Napalkov P, "Time Trends of Idiopathic Pulmonary Fibrosis (IPF) in the United Kingdom From 1999 to 2013 Using the Clinical Practice Research Datalink (CPRD)", Poster presented at 32nd ICPE Conference, Dublin Ireland, August 25-28, 2016
  • Yong M, Chia J, Oliveri D, Chen H, Cheung D, Raimundo K, Cohen M, Napalkov P, "Incidence and Prevalence Time Trends of Idiopathic Pulmonary Fibrosis in the United States Over a 14-Year Period—A Claims Database Study", Poster presented at 32nd ICPE Conference, Dublin Ireland, August 25-28, 2016
  • Alexander M, Petri H, Ding Y, Wandel C, Khwaja O, Foskett N, “Morbidity and medication in large population of people with Dawn syndrome compared to the general population”, Developmental Medicine & Child Neurology, July 2015; early view published online
  • Alexander M1, Ding Y2, Foskett N1, Petri H3, Wandel C4, Khwaja O5. "Population prevalence of Down's syndrome in the United Kingdom." J Intellect Disabil Res. 2016 Mar 28. doi: 10.1111/jir.12277.
  • Arikian SR, Binder G, Gibson C, Hu XH, Nagarwala Y, Hussein MA, Corvino FA, Lee J, Surinach A, Kaura S, Usmani S. “Patterns of Total Costs of Care over Time for Patients with Multiple Myeloma (MM)”. Abstract accepted for 57th American Society of Hematology Annual Meeting & Exposition, Orlando FL, December 5-8, 2015
  • Arikian SR, Binder G, Gibson CJ, Hu XH, Nagarwala Y, Hussein M, Corvino FA, Surinach A, Usmani S. “Patterns of Total Cost of Care by Age Group for Patients with Newly Diagnosed Multiple Myeloma (MM)”. Poster presented at 20th Congress of European Hematology Association, Austria, Vienna, June 11-14, 2015
  • Arikian SR, Milentijevic D, Binder G, Corvino FA, Surinach A, et al. “Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma”, Curr Med Res Opin. 2015; 31 (6):1105-15
  • Arikian SR, Nyandege A, Binder G, Hu XH, Nagarwala, Hussein M, Lee J, Corvino FA, Surinach A, Usmani SZ. “Patterns of Growth Factor Costs in Multiple Myeloma Patients Treated with Lenalidomide or Bortezomib”. Poster presented at 15th International Myeloma Workshop, Rome, Italy, September 23-26, 2015
  • Arnieri B, Sarsour K, Oliveri D, Petho-Schramm A, Shah A, Quartey G. “Comparison of Oral Glucocorticoid-Sparing Effects in Tocilizumab and Other Biologic DMARDs Using Multilevel Models in Administrative Health Care Claims Database”, Poster presented at 2015 ACR/ARHP Annual Meeting, San Francisco, CA, November 6-11, 2015
  • Looney W. Epidemiology Arising. Executive Roundtable featuring Blackburn S, Cohen J, Doyle J, Locklear JC, Neugut A, Reynolds R, Stang P. Pharmaceutical Executive. Aug 2015; 16-25.
  • DeZern AE, Binder G, Fliss A, Hu XH, Rizvi S, Corvino FA, Arikian SR, Surinach A, Lee J, Smith BD. “Relationship Between Lenalidomide Dose Modification and Outcomes in Patients with Myelodysplastic Syndromes”. Abstract accepted for 57th American Society of Hematology Annual Meeting & Exposition, Orlando FL, December 5-8, 2015
  • Kauf T, Xu P, Zivkovic M, Corvino FA, “Cost Implications of Tedizolid use in acute Bacterial Skin and Skin Structure Infection (Abssi) for Hospitals and Managed care organizations (Mcos)”, Value in Health, May 2015, 18 (3): A240
Please contact us for a full publication list

careers

Our team includes graduates from the world’s top universities, accomplished professionals, physicists and epidemiologists, specialists and generalists; we are always in search of the right people to join our team.
WE ARE LOOKING FOR
Creative, brave and enthusiastic professionals to join our growing team and help us further push the boundaries of our research.

Senior Analyst
Research Analyst

Contact Us

Email
info@genesisrg.com

Phone
T+1 888 503 2680

Address
5 Marine View Plaza, Suite 312
Hoboken NJ 07030